Alfonso José F, Fernández-Vega-Cueto Luis, Alfonso-Bartolozzi Belén, Montés-Micó Robert, Fernández-Vega Luis
J Refract Surg. 2019 Mar 1;35(3):169-176. doi: 10.3928/1081597X-20190118-01.
To assess the long-term correction of moderate to high myopia using a posterior chamber phakic intraocular lens with a central port design.
Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, intraocular pressure (IOP), endothelial cell density (ECD), vault, and adverse events over a 5-year period were evaluated retrospectively.
A total of 147 eyes (83 patients) were evaluated. Mean postoperative UDVA and CDVA were 0.05 ± 0.11 and 0.02 ± 0.08 logMAR at 1 year and 0.13 ± 0.18 and 0.02 ± 0.09 logMAR at 5 years, respectively. More than 95% of eyes achieved CDVA of 20/25 or better at both follow-up periods. CDVA was unchanged or improved from one to three or more lines in all eyes. Preoperatively, mean spherical equivalent (SE) was -9.20 ± 3.02 diopters (D). At 1 year, the mean SE was -0.17 ± 0.26 D, with 91.53% of eyes within ±0.50 D and 100% of eyes within ±1.00 D of the target. At 5 years, the mean SE was -0.44 ± 0.47 D, with 67.4% of eyes within ±0.50 D and 90.1% of eyes within ±1.00 D of the target. Mean IOP was 12.74 ± 1.65 and 13.0 ± 2.03 mm Hg, at 1 and 5 years, respectively. No significant rise in IOP (> 20 mm Hg) occurred during the follow-up period. Mean ECD was 2,696 ± 358 and 2,645 ± 359 cells/mm at 1 and 5 years, respectively, representing a non-significant loss of 0.43% from preoperative values (P = .304). Mean vault changed significantly from 398 ± 187 µm at 1 year to 340 ± 163 µm at 5 years (P < .001). No intraoperative or postoperative complications or adverse events occurred during the follow-up period.
The good long-term outcomes found in this study support the use of this lens with a central port design for the correction of moderate to high myopia. [J Refract Surg. 2019;35(3):169-176.].
使用具有中央端口设计的后房型有晶状体眼人工晶状体评估中高度近视的长期矫正效果。
回顾性评估5年期间的未矫正远视力(UDVA)、矫正远视力(CDVA)、屈光、眼压(IOP)、内皮细胞密度(ECD)、前房深度以及不良事件。
共评估了147只眼(83例患者)。术后1年时平均UDVA和CDVA分别为0.05±0.11和0.02±0.08 logMAR,5年时分别为0.13±0.18和0.02±0.09 logMAR。在两个随访期内,超过95%的眼睛CDVA达到20/25或更好。所有眼睛的CDVA保持不变或提高了一行或多行。术前平均球镜等效度(SE)为-9.20±3.02屈光度(D)。1年时,平均SE为-0.17±0.26 D,91.53%的眼睛在目标值±0.50 D范围内,100% 的眼睛在目标值±1.00 D范围内。5年时,平均SE为-0.44±0.47 D,67.4%的眼睛在目标值±0.50 D范围内,90.1%的眼睛在目标值±1.00 D范围内。1年和5年时平均眼压分别为12.74±1.65和13.0±2.03 mmHg。随访期间未出现眼压显著升高(>20 mmHg)的情况。1年和5年时平均ECD分别为2,696±358和2,645±359个细胞/mm²,较术前值无显著下降,下降了0.43%(P = .304)。平均前房深度从1年时的398±187 µm显著变化为5年时的340±163 µm(P < .001)。随访期间未发生术中或术后并发症或不良事件。
本研究中发现的良好长期结果支持使用这种具有中央端口设计的晶状体来矫正中高度近视。[《屈光手术杂志》。2019年;35(3):169 - 176。]